Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00004003 · ClinicalTrials.gov registry record · Phase 2

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Pancreatic Cancer That Cannot Be Removed by Surgery

A Phase 2 study of Pancreatic Cancer, sponsored by Barbara Ann Karmanos Cancer Institute.

Completed
Registry status
Phase 2
Development phase
30
Enrollment target
1
Study location

NCT00004003: Completed Phase 2 study of Pancreatic Cancer, sponsored by Barbara Ann Karmanos Cancer Institute.

NCT00004003 is a Phase 2 study of Pancreatic Cancer that has completed, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 30 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00004003, a Phase 2 study of Pancreatic Cancer, has completed, sponsored by Barbara Ann Karmanos Cancer Institute.

COMPLETED
Registry status
Phase 2
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating adult patients who have stage III or stage IV pancreatic cancer that cannot be removed by surgery.

Conditions Studied

Pancreatic Cancer

Interventions

  • DRUG cisplatin
  • DRUG fluorouracil
  • DRUG gemcitabine hydrochloride

Study Locations (1)

Michigan

  • Barbara Ann Karmanos Cancer Institute - Detroit

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 1999-04
Est. Completion 2003-08
Phase Phase 2
Barbara Ann Karmanos Cancer Institute

139 total trials

What the finished NCT00004003 record still lists

NCT00004003 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (92% lower).

The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 3 interventions - of which cisplatin is the first listed.

NCT00004003 reports a single indexed study location in Michigan.

Frequently Asked Questions

What is clinical trial NCT00004003 about?

NCT00004003 is a clinical study titled "Combination Chemotherapy in Treating Patients With Stage III or Stage IV Pancreatic Cancer That Cannot Be Removed by Surgery". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating adult patients who have stage II...

What is the current status of trial NCT00004003?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 1999-04. Estimated completion is 2003-08.

What conditions does trial NCT00004003 study?

This clinical trial studies the following conditions: Pancreatic Cancer.

What interventions are being tested in trial NCT00004003?

The interventions under investigation include: cisplatin (DRUG), fluorouracil (DRUG), gemcitabine hydrochloride (DRUG).

Who is sponsoring clinical trial NCT00004003?

This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00004003 being conducted?

This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pancreatic Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00004003's enrollment target sits among peer trials

30 189th of 278 higher than 83 of 278 other Pancreatic Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00004003, the US trial registry maintained by the National Library of Medicine. NCT00004003 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.